Journey Medical Corporation

Equities

DERM

US48115J1097

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
4.02 USD -9.05% Intraday chart for Journey Medical Corporation -2.19% -30.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea CI
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting CI
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target MT
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea CI
Journey Medical Signs Credit Facility of up to $20 Million MT
Journey Medical Corporation Secures Credit Facility with SWK Holdings for Up to $20 Million CI
Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors CI
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating MT
Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea CI
Journey Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Journey Medical Corporation, Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Reports Q3 Revenue $34.5M MT
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q3 EPS $0.99 MT
Journey Medical Says Study Shows Bioavailability of Minocycline Lower After One Dose of DFD-29 Compared With Solodyn MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 CI
Insider Buy: Journey Medical MT
Journey Medical Grants Exclusive License to Maruho for Manufacturing, Commercialization of Qbrexza in Asia MT
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations CI
Transcript : Journey Medical Corporation, Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q2 Revenue $17.2M MT
Journey Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Journey Medical Corporation Announces Impairment Charges for the Second Quarter Ended June 30, 2023 CI
Chart Journey Medical Corporation
More charts
Journey Medical Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes over eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products that have been approved by the United States Food and Drug Administration (FDA) for sale include Qbrexza, Accutane, Targadox, Ximino, and Exelderm Cream and Solution. The Company's product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne, and Exelderm Cream and Solution is an antifungal intended for topical use.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.02 USD
Average target price
8.25 USD
Spread / Average Target
+105.22%
Consensus
  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation
  5. Journey Medical, Padagis US Reach Settlement Agreement for Qbrexza, Amzeeq, Zilxi Patent Exclusivity